129 related articles for article (PubMed ID: 35373021)
21. Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).
Isaka Y; Fujii H; Tsujimoto Y; Teramukai S; Hamano T
Clin Exp Nephrol; 2018 Aug; 22(4):967-972. PubMed ID: 29536389
[TBL] [Abstract][Full Text] [Related]
22. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
23. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.
Bhargava R; Kalra PA; Hann M; Brenchley P; Hurst H; Hutchison AJ
BMC Nephrol; 2019 Feb; 20(1):37. PubMed ID: 30717691
[TBL] [Abstract][Full Text] [Related]
24. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
25. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis.
Saif I; Halim A; Altaf A; Saif M; Khalid M; Ahmad D; Imran H
J Ayub Med Coll Abbottabad; 2007; 19(4):26-8. PubMed ID: 18693591
[TBL] [Abstract][Full Text] [Related]
26. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
27. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
28. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
[TBL] [Abstract][Full Text] [Related]
29. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Shigematsu T;
Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of a Nutritional Mobile Application for Management of Hyperphosphatemia in Patients on Hemodialysis: A Multicenter Open-Label Randomized Clinical Trial.
Teong LF; Khor BH; Ng HM; Sahathevan S; Purba KR; Narayanan SS; Gafor AHA; Goh BL; Bee BC; Yahya R; Bavanandan S; Wahab Z; Mazlan SA; Chinna K; Morad Z; Daud ZAM; Karupaiah T
J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743746
[TBL] [Abstract][Full Text] [Related]
31. Impact of using two dialyzers in parallel on phosphate clearance in hemodialysis patients: a randomized trial.
Thompson S; Manns B; Lloyd A; Hemmelgarn B; MacRae J; Klarenbach S; Unsworth L; Courtney M; Tonelli M
Nephrol Dial Transplant; 2017 May; 32(5):855-861. PubMed ID: 27190374
[TBL] [Abstract][Full Text] [Related]
32. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
33. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
34. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
St Peter WL; Wazny LD; Weinhandl ED
Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
[TBL] [Abstract][Full Text] [Related]
35. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
[TBL] [Abstract][Full Text] [Related]
36. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
[TBL] [Abstract][Full Text] [Related]
37. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
38. Phosphate Control in Peritoneal Dialysis Patients: Issues, Solutions, and Open Questions.
Cernaro V; Calderone M; Gembillo G; Calabrese V; Casuscelli C; Lo Re C; Longhitano E; Santoro D
Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513579
[TBL] [Abstract][Full Text] [Related]
39. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
[TBL] [Abstract][Full Text] [Related]
40. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
